SKAN Group AG (SKAN) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of SKAN Group AG CHF 33.93, price CHF 69.00, upside -50.8%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SKAN Group AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
59‑month range CHF 40.21 – CHF 89.80 · fair‑value band CHF 17.90 – CHF 59.26 · the CHF 69.00 price screens above the CHF 33.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow SKAN Group in your weekly email
Every Wednesday you see whether SKAN Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables.
Show more
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables. The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar flow, particle counter, personal protective equipment, safety workbench, transfer systems, and fume cupboard. It also provides digital solutions, lifecycle support, laboratory services, and SKAN labs. The company was formerly known as BV Holding AG and changed its name to SKAN Group AG in October 2021. SKAN Group AG was founded in 1968 and is headquartered in Allschwil, Switzerland.
Stock analysis
SKAN Group AG (SKAN) currently trades at CHF 69.00, while our model-based Fair Value estimate is CHF 33.93, implying the stock looks roughly 103.4% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of CHF 33.63 per share, and 0 of the 25 models we run sit above the CHF 69.00 price.
Bear case: the Asset-Based group reads lowest at CHF 3.41, and 25 of the 25 models stay below the price. Evidence for this calculation is medium.
Scenario range: CHF 17.90 (bear) to CHF 59.26 (bull), the price of CHF 69.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SKAN Group AG reported revenue of CHF 333M in FY2025 versus CHF 234M in FY2021, a compound +9.2%/yr. Reported net income was CHF 16.3M in FY2025, compounding +11.3%/yr from FY2021.
Key figures
Market cap CHF 1.6B · P/E ratio 95.8 · P/S ratio 4.68 · EPS (TTM) CHF 0.7200 · Dividend yield 0.3% · Net margin 4.9% · Return on equity 10.6% · Return on assets (EBIT) 8.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 72% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −51%, SKAN screens richer than that median.
Fair Value models
Bear CHF 17.90Fair Value CHF 33.93Bull CHF 59.26
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 0.3658 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−7.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Start year 2020 (pandemic). Over 10 years: +32.3% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−7.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.0%
Dividend (yield on the price)0.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3% vs −7%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 8%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+37.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Switzerland: IMF forecast 0.6% a year to 2030, 0.8% from 2016 to 2025) that is about +36.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
Beats the industry median on 3/14 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−51% · Below median
Profitability
Return on equity (TTM)11% · Above median
Return on assets4% · Above median
Net margin (TTM)5% · Below median
Operating margin (TTM)15% · Above median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity1.09× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)95.8× · Priciest 25%
P/B16.44× · Priciest 25%
P/S (TTM)5.65× · Priciest 25%
P/FCF89.6× · Priciest 25%
EV/EBITDA53.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)3· sector 31
PAST (return on equity)43· sector 25
HEALTH (low debt)45· sector 96
DIVIDEND (yield)6· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SKAN Group AG Fair Value". https://www.fairvalue-calculator.com/stock/SKAN
Frequently asked questions
Is SKAN Group AG (SKAN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of CHF 33.93 versus a price of CHF 69.00, about −51% upside (overvalued).
What is the fair value of SKAN?
Our model-based fair value for SKAN Group AG is CHF 33.93 (as of Sep 23, 2026), built from audited fundamentals. The current price: CHF 69.00.
What is the quality score of SKAN?
SKAN Group AG has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SKAN Group AG (SKAN)?
Our model-based price target is the fair value of CHF 33.93 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario CHF 17.90, optimistic scenario CHF 59.26. It is a calculation from audited fundamentals, not an analyst target.
What is the SKAN Group AG stock forecast for 2026?
Our models put fair value at CHF 33.93, about −51% upside versus a price of CHF 69.00 (overvalued). Cautious scenario CHF 17.90, optimistic scenario CHF 59.26. The calculation is refreshed regularly with new filings.
What is the revenue of SKAN Group AG (SKAN)?
SKAN Group AG reported trailing-twelve-month revenue of about CHF 333M (latest available figure, as of Sep 23, 2026).
Does SKAN Group AG pay a dividend?
SKAN Group AG currently shows a dividend yield of about 0.32% relative to its recent price (as of Sep 23, 2026).
What growth is priced into SKAN Group AG (SKAN)?
For today's price to be fair in a discounted-cash-flow model, SKAN Group AG would have to grow free cash flow by +37.0 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of SKAN use?
Our models discount SKAN Group AG at 10.3 %: a base by market capitalisation (small), damped by beta 0.74, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SKAN Group AG that is +37.0 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has SKAN Group AG (SKAN) delivered so far?
Over the past 5 years revenue at SKAN Group AG grew +11.7 % a year. The price currently implies +37.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of SKAN Group AG (SKAN) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into SKAN Group AG (+37.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of SKAN Group AG (SKAN)?
The free-cash-flow yield on the price is 1.35 %: that much free cash flow SKAN Group AG produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SKAN Group AG (SKAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SKAN Group AG it is CHF 33.93 per share (as of Sep 23, 2026), against a price of CHF 69.00. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is SKAN Group AG stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SKAN trades above its calculated fair value: price CHF 69.00, fair value CHF 33.93, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SKAN?
No. The price is what the market pays today (CHF 69.00); the fair value is what the company's own numbers justify (CHF 33.93). For SKAN Group AG the two are CHF 35.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is SKAN Group AG worth?
The market values SKAN Group AG at about CHF 1.6B (market capitalisation, as of Sep 23, 2026). Per share that is CHF 69.00; our models calculate a fair value of CHF 33.93 per share.
What do the bullish and bearish scenarios say about SKAN?
Our models span a range for SKAN Group AG: cautious scenario CHF 17.90, base CHF 33.93, optimistic CHF 59.26 per share (as of Sep 23, 2026, price CHF 69.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SKAN?
SKAN Group AG trades at a price-to-earnings ratio of 95.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 33.93 is built from several models across several years. Other multiples: P/B 16.4, P/S 5.6, EV/EBITDA 53.9.
How solid is the balance sheet of SKAN Group AG (SKAN)?
Balance-sheet figures for SKAN Group AG (as of Sep 23, 2026): return on equity 10.6%, debt of 1.09 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is SKAN from its 52-week high?
SKAN Group AG trades at CHF 69.00, at its 52-week high of CHF 69.00 and 72% above the low of CHF 40.21 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 33.93 is for.
Which stocks are comparable to SKAN Group AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SKAN Group AG stock attractive at the current price?
The data as of Sep 23, 2026: price CHF 69.00, calculated fair value CHF 33.93 (−51%), Quality Score 52/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SKAN calculated?
We run SKAN Group AG through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 33.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. SKAN Group AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SKAN Group AG (SKAN)?
The closing price on Sep 23, 2026 was CHF 69.00. Our model-based fair value is CHF 33.93, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SKAN Group AG right now?
The price sits above even our optimistic bull case (CHF 59.26). The favourable scenario is already priced in. The model range is unusually wide (CHF 17.90 to CHF 59.26). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of SKAN Group AG (SKAN) come from?
Earnings per share at SKAN Group AG grew −0.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +30.9 %, EBIT margin −21.7 %, tax rate −1.9 %, residual (interest, one-offs) −1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of SKAN Group AG
How large is the market capitalisation of SKAN Group AG (SKAN)?
The market capitalisation of SKAN Group AG is CHF 1.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SKAN Group AG (SKAN)?
The price-to-sales ratio of SKAN Group AG is 4.68 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SKAN Group AG (SKAN)?
Earnings per share at SKAN Group AG are CHF 0.7200 (price ÷ EPS = P/E 95.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SKAN Group AG (SKAN)?
The dividend yield of SKAN Group AG is 0.3% (payout 30.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SKAN Group AG (SKAN)?
The net margin of SKAN Group AG is 4.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SKAN Group AG (SKAN)?
The return on equity (ROE) of SKAN Group AG is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SKAN Group AG (SKAN)?
On an EBIT basis the return on assets of SKAN Group AG is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SKAN Group AG (SKAN)?
The operating margin of SKAN Group AG is 15.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SKAN Group AG (SKAN)?
Revenue at SKAN Group AG is growing +0.6% versus a year earlier (3y avg +6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SKAN Group AG (SKAN)?
Earnings per share at SKAN Group AG are growing +0.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does SKAN Group AG (SKAN) carry?
The net debt of SKAN Group AG is CHF 37.4M (fiscal year 2025, ≈ 1.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SKAN Group AG in the live analysis
One click puts SKAN Group AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
